Yayınlar & Eserler

Yayın Ağı
SCI, SSCI ve AHCI İndekslerine Giren Dergilerde Yayınlanan Makaleler 180

1. Metastatic colorectal cancer in both sides of Aegean sea: practice patterns and outcome

YAZICI O., Ucar G., SÜTCÜOĞLU O., Turhal N. S., Yildiz B., Karamouzis M., et al.
Current Medical Research and Opinion , cilt.38, ss.579-586, 2022 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

2. Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE

Gunes A. K., Dagdas S., Ceran F., Ucar M. A., Falay M., Sunu C., et al.
Indian Journal of Hematology and Blood Transfusion , cilt.37, sa.1, ss.82-89, 2021 (SCI-Expanded) identifier identifier identifier

3. Clinical outcomes of patients with pure small cell carcinoma of the urinary bladder

Erdem G. U., Dogan M., Aytekin A., Sahin S., Cinkir H. Y., Sakin A., et al.
Irish Journal of Medical Science , cilt.189, sa.2, ss.431-438, 2020 (SCI-Expanded) identifier identifier identifier

4. A rare case: Branch retinal vein occlusion associated with the use of tamoxifen

DEMİRCİ N. S., Erdem G., Uçgun N., Bozkaya Y., Ozdemir N., Dogan M., et al.
Journal of Cancer Research and Therapeutics , cilt.15, sa.3, ss.722-724, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

5. The frequency and predictors of persistent amenorrhea in premenopausal women with colorectal cancer who received adjuvant chemotherapy

Sahin T., Dizdar O., Ozdemir N., ZENGİN N., Ates O., Oksuzoglu B., et al.
Anti-Cancer Drugs , cilt.30, sa.3, ss.289-294, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

6. Prognostic importance of the albumin to globulin ratio in metastatic gastric cancer patients

Bozkaya Y., Erdem G. U., DEMİRCİ N. S., Yazıcı O., Özdemir N. Y., Köstek O., et al.
Current Medical Research and Opinion , cilt.35, sa.2, ss.275-282, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

7. Is the Charlson comorbidity index a prognostic indicator for toxicity and mortality in elderly patients with locally advanced rectal cancer?

Köstek O., Bozkaya Y., Hacıoğlu M. B., Özdemir N. Y., Yılmaz E., Demircan N. C., et al.
Archives of Iranian Medicine , cilt.22, sa.5, ss.236-241, 2019 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

8. Mortality risk analysis of asymptomatic and symptomatic venous thromboembolism in patients with metastatic colorectal cancer

Bozkaya Y., Özdemir N., Erdem G., DEMİRCİ N. S., Yazici O., Hocazade C., et al.
Journal of Cancer Research and Therapeutics , cilt.14, sa.6, ss.1330-1335, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

9. Neutrophil–lymphocyte ratio, platelet–lymphocyte ratio, neutrophil–platelet score and prognostic nutritional index: do they have prognostic significance in metastatic pancreas cancer?

Dogan M., Algin E., Guven Z. T., Baykara M., Kos T. F., Bal O., et al.
Current Medical Research and Opinion , cilt.34, sa.5, ss.857-863, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

10. Non-Urothelial Bladder Cancer: Comparison of Clinicopathological and Prognostic Characteristics in Pure Adenocarcinoma and Non-Bilharzial Squamous Cell Carcinoma of the Bladder

Erdem G. U., Dogan M., Sakin A., Oruc Z., Yaman E., Yesil Cinkir H., et al.
Oncology Research and Treatment , cilt.41, sa.4, ss.220-225, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

11. A modified epirubicin and oxaliplatin plus capecitabine (EOX) regimen as a second- line therapy in patients with advanced gastric cancer

Bozkaya Y., Özdemir N. Y., Yazici O., DEMİRCİ N. S., Kurtipek A., Erdem G. U., et al.
Asian Pacific Journal of Cancer Prevention , cilt.19, sa.1, ss.283-290, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

12. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane

Erdem G. U., Bozkaya Y., Ozdemir N. Y., DEMİRCİ N. S., Yazici O., ZENGİN N.
Bosnian Journal of Basic Medical Sciences , cilt.18, sa.2, ss.170-177, 2018 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

13. Is serum survivin expression a predictive biomarker in locally advanced gastric cancer patients treated with neoadjuvant chemotherapy?

Bozkaya Y., Özdemir N. Y., Sezer S., Köstek O., DEMİRCİ N. S., Yazlcl O., et al.
Cancer Biomarkers , cilt.22, sa.1, ss.143-149, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

14. Advanced signet-ring cell carcinoma of the stomach: Clinicopathological characteristics of patients and efficacy of the modified docetaxel, cisplatin, and fluorouracil regimen

Bozkaya Y., Erdem G. U., Özdemir N. Y., Hocazade C., Yazici O., DEMİRCİ N. S., et al.
Journal of Cancer Research and Therapeutics , cilt.14, sa.10, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

15. Preoperative platelet-to-lymphocyte ratio is a predictor of prognosis in patients with ampullary carcinoma

DEMİRCİ N. S., Ozdemir N., Erdem G., Bozkaya Y., Yazici O., ZENGİN N.
Bratislava Medical Journal , cilt.119, sa.3, ss.180-186, 2018 (SCI-Expanded) Creative Commons License identifier identifier identifier

16. Comparison of gemcitabine monotherapy with gemcitabine and cisplatin combination in metastatic pancreatic cancer: A retrospective analysis

Ergun Y., Ozdemir N. Y., Guner E. K., Esin E., Sendur M. A., Koksoy E. B., et al.
Journal of B.U.ON. , cilt.23, ss.116-121, 2018 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

17. Evaluation of Lymphoma Patients Receiving High-Dose Therapy and Autologous Stem Cell Transplantation: Experience of a Single Center

Bozkaya Y., Uncu D., Dağdaş S., Erdem G. U., Doğan M., Özet G., et al.
Indian Journal of Hematology and Blood Transfusion , cilt.33, sa.3, ss.361-369, 2017 (SCI-Expanded) Creative Commons License identifier identifier identifier

18. Effectiveness of low-dose oral etoposide treatment in patients with recurrent and platinum-resistant epithelial ovarian cancer

Bozkaya Y., Doğan M., Umut Erdem G., Tulunay G., Uncu H., Arık Z., et al.
Journal of Obstetrics and Gynaecology , cilt.37, sa.5, ss.649-654, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

19. Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy

Bozkaya Y., Ozdemir N., Colak A., ZENGİN N.
Journal of B.U.ON. , cilt.22, sa.4, ss.919-925, 2017 (SCI-Expanded) identifier identifier

20. Is plasma caveolin-1 level a prognostic biomarker in metastatic pancreatic cancer?

DEMİRCİ N. S., Dogan M., Erdem G. U., Kacar S., Turhan T., Kilickap S., et al.
Saudi Journal of Gastroenterology , cilt.23, sa.3, ss.183-189, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

21. Comparison of pigmentary side effects of taxanes and anthracyclines: an onychoscopic evaluation

Yorulmaz A., Dogan M., Artuz F., ZENGİN N.
Cutaneous and Ocular Toxicology , cilt.36, sa.2, ss.135-139, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

22. Modified docetaxel, cisplatin and fluorouracil therapy as the first-line treatment for patients with recurrent/metastatic squamous cell carcinoma of the head and neck cancer: a retrospective study

Demirci N. S., Aksoy S., Özdemir N. Y., Erdem G. U., Ozcelik M., Tanrikulu E., et al.
Current Medical Research and Opinion , cilt.33, sa.3, ss.401-407, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

23. Comparative study of receptor discordance between primary and corresponding metastatic lesions in breast cancer

Erdem G. U., Altundag K., Ozdemir N. Y., Sahin S., Demirci N. S., Karatas F., et al.
Journal of B.U.ON. , cilt.22, sa.2, ss.365-376, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

24. Comparison of clinicopathological and prognostic characteristics in patients with mucinous carcinoma and signet ring cell carcinoma of the stomach

Bozkaya Y., Erdem G. U., Ozdemir N. Y., DEMİRCİ N. S., Hocazade C., Yazıcı O., et al.
Current Medical Research and Opinion , cilt.33, sa.1, ss.109-116, 2017 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

25. Reduced doses of docetaxel and cisplatinum plus 5 fluorouracil combination chemotherapy in metastatic esophagogastric adenocarcinoma: The impact on outcomes Metastatik özofagogastrik adenokarsinomlarda modifiye doz dosetaksel-sisplatin-5-fluorourasil kombinasyon tedavisi: Sonuçlara etkisi

Eren T., Ozdemir N., Yazici O., Imamoglu G. I., Yazilitas D., ARSLAN S. O., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.27, sa.3, ss.171-177, 2017 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

26. A new angiogenesis prognostic index with VEGFA, PLGF, and angiopoietin 1 predicts survival in patients with advanced gastric cancer

Aktaş S. H., AKBULUT H., Yazici O., ZENGİN N., Akgün H. N., Üstüner Z., et al.
Turkish Journal of Medical Sciences , cilt.47, sa.2, ss.399-406, 2017 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

27. Adding chemotherapy after neoadjuvant chemoradiation in locally advanced rectal cancer; Promising or not?

ŞENDUR M. A. N., Bilgin B., AKSOY S., Akinci B., Ozdemir N., Dede D. S., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.27, sa.3, ss.194-196, 2017 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

28. Flare phenomenon in advanced colorectal cancer: Cessation of bevacizumab after predefined cycles of therapy may not affect outcome İleri evre kolorektal kanserli hastalarda alevlenme fenomeni: Önceden belirlenmiş sayida verilen bevasizumabin kesilmesi sağkalimi olumsuz etkilemeyebilir

Besen A. A., Kose F., Sumbul A. T., Ozdemir N., Ozyilkan O., ZENGİN N., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.27, sa.1, ss.53-59, 2017 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

29. Prognostic effect of symptomatic and asymptomatic venous thromboembolism in patients with gastric cancer Mide kanserli hastalarda semptomatik ve asemptomatik venöz tromboembolizmin prognostik etkisi

Bozkaya Y., Ozdemir N., DEMİRCİ N. S., Erdem G. U., Yazici O., Arslan S., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.27, sa.2, ss.100-109, 2017 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

30. The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma

Bozkaya Y., Doğan M., Yazıcı O., Erdem G. U., DEMİRCİ N. S., ZENGİN N.
Bosnian Journal of Basic Medical Sciences , cilt.17, sa.2, ss.138-143, 2017 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

31. The clinical and pathological features affecting the time of relapse in patients with early stage colorectal cancer

Yazilitas D., Özdemir N., Yazici O., Hocazade C., DEMİRCİ N. S., ZENGİN N.
Journal of Cancer Research and Therapeutics , cilt.12, sa.4, ss.1257-1260, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

32. Prognostic role of pretreatment platelet/lymphocyte ratio in patients with non-small cell lung cancer

Kos M., Hocazade C., Kos F. T., Uncu D., Karakas E., Dogan M., et al.
Wiener Klinische Wochenschrift , cilt.128, sa.17-18, ss.635-640, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

33. Accessory spleen hypertrophy mimicking colon cancer metastasis

Ates I., Yazici O., Yazilitas D., Ozdemir N., ZENGİN N.
Experimental Oncology , cilt.38, sa.3, ss.202-203, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

34. Impact of laboratory test use strategies in a Turkish hospital

Yilmaz F. M., Kahveci R., Aksoy A., Kucuk E. Ö., Akin T., Mathew J. L., et al.
PLoS ONE , cilt.11, sa.4, 2016 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

35. Evaluation of prognostic factors in localized high-grade undifferentiated pleomorphic sarcoma: report of a multi-institutional experience of Anatolian Society of Medical Oncology

Ozcelik M., Seker M., Eraslan E., Koca S., Yazilitas D., Ercelep O., et al.
Tumor Biology , cilt.37, sa.4, ss.5231-5237, 2016 (SCI-Expanded) identifier identifier identifier

36. Oxaliplatin-induced acute thrombocytopenia

Erdem G., Dogan M., DEMİRCİ N. S., ZENGİN N.
Journal of Cancer Research and Therapeutics , cilt.12, sa.2, ss.509-514, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

37. Small cell carcinoma of the urinary bladder: Changing trends in the current literature

Erdem G. U., Özdemir N. Y., DEMİRCİ N. S., Şahin S., Bozkaya Y., ZENGİN N.
Current Medical Research and Opinion , cilt.32, sa.6, ss.1013-1021, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

38. The effect of the gastrectomy on survival in patients with metastatic gastric cancer: A study of ASMO

Yazici O., Özdemir N., Duran A. O., Menekşe S., Nahit Şendur M. A., Karaca H., et al.
Future Oncology , cilt.12, sa.3, ss.343-354, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

39. First hematopoietic cell transplantation in Uzbekistan: Progress through education and cooperation

Karimov K., Tekgündüz E., Saidov A., Kayikçi Ö., Boboev K., Koçubaba Ş., et al.
Transfusion and Apheresis Science , cilt.54, sa.1, ss.60-62, 2016 (SCI-Expanded) identifier identifier identifier

40. Targeted therapies are new hope for patients with spinal radionecrosis

Hocazade C., Ozdemir N. Y., Yazici O., Oztekin Z. N., ZENGİN N.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.26, sa.2, ss.126-128, 2016 (SCI-Expanded) Creative Commons License identifier identifier

41. Effect of body mass index on the efficacy of adjuvant tamoxifen in premenopausal patients with hormone receptor positive breast cancer

ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., ZENGİN N., Yazici O., Sever A. R., et al.
Journal of B.U.ON. , cilt.21, sa.1, ss.27-34, 2016 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

42. A retrospective comparison of early stage primary extranodal with nodal non-Hodgkin lymphoma patients: A single center experience

Yazilitas D., Özdemir N., Hocazade C., Bozkaya Y., Yazici O., ŞENDUR M. A. N., et al.
Journal of B.U.ON. , cilt.20, sa.6, ss.1526-1533, 2015 (SCI-Expanded) identifier identifier identifier

43. Squamous cell and neuroendocrine carcinoma of esophagus: Collision versus composite tumor: A case report and review of literature

Yazici O., AKSOY S., Ozhamam E., ZENGİN N.
Indian Journal of Cancer , cilt.52, sa.4, ss.603-604, 2015 (SCI-Expanded) identifier identifier identifier

44. A rare case: Hallucination associated with pazopanib

DEMİRCİ N. S., Erdem G. U., Dogan M., Ozdemir N. Y., ZENGİN N.
Journal of Cancer Research and Therapeutics , cilt.11, sa.4, ss.961-962, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

45. Rectal cancer with metastasis to the face

Yazilitas D., Dogan M., Ileri A. B., Ozdemir N., DEMİRCİ N. S., ZENGİN N.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.25, sa.2, ss.145-147, 2015 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

46. The relationship between platelet-lymphocyte ratio, neutrophil-lymphocyte ratio, and survival in metastatic gastric cancer on firstline modified docetaxel and cisplatinum plus 5 Fluorourasil Regimen: A single institute experience

Dogan M., Eren T., Ozdemir N., Cigirgan C. L., ZENGİN N.
Saudi Journal of Gastroenterology , cilt.21, sa.5, ss.320-324, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

47. Unusual metastases of lung cancer: bulbus oculi and maxillary sinus

Ates I., Yazici O., Ates H., Ozdemir N., ZENGİN N.
Experimental oncology , cilt.37, sa.3, ss.231-232, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

48. Concordance of positron emission tomography and computed tomography in patients with locally advanced gastric and esophageal cancer

Hocazade C., Özdemir N., Yazici O., Bozkaya Y., Yazılıtaş D., Toptaş Ş., et al.
Annals of Nuclear Medicine , cilt.29, sa.7, ss.621-626, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

49. The effect of obesity on recurrence pattern in early breast cancer patients

Yazici O., AKSOY S., Sendur M. A. N., Babacan T., Ozdemir N., Ozisik Y., et al.
Journal of B.U.ON. , cilt.20, sa.4, ss.954-962, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

50. Actual benefit of chemo-hormonal therapy in non-castrate metastatic prostate cancer

ŞENDUR M. A. N., AKINCI M. B., Ozdemir N. Y., AKSOY S., Dede D. S., Ulas A., et al.
Future Oncology , cilt.11, sa.8, ss.1141-1143, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

51. A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma

Erdem G. U., Sendur M. A. N., Ozdemir N. Y., Yazici O., ZENGİN N.
Current Medical Research and Opinion , cilt.31, sa.4, ss.743-756, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

52. Comparison of the long term cardiac effects associated with 9 and 52 weeks of trastuzumab in HER2-positive early breast cancer

ŞENDUR M. A. N., AKSOY S., YORGUN H., Ozdemir N., Yilmaz F. M., Yazici O., et al.
Current Medical Research and Opinion , cilt.31, sa.3, ss.547-556, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

53. Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer

Nahit Şendur M. A., AKSOY S., Bülent Akinci M., Ozdemir N., ŞENER DEDE D., Altundag K., et al.
Future Oncology , cilt.11, sa.6, ss.905-907, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

54. Association between blood urea nitrogen/albumin ratio and prognosis in non-small cell lung cancer

Kos M., Hocazade C., Kos F. T., Uncu D., Karakas E., Dogan M., et al.
Acta Medica Mediterranea , cilt.31, sa.2, ss.219-223, 2015 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

55. Efficacy of dose dense doxorubicin and cyclophosphamide followed by paclitaxel versus conventional dose doxorubicin, cyclophosphamide followed by paclitaxel or docetaxel in patients with node-positive breast cancer: A retrospective study of the Anatolian Society of Medical Oncology

Yazilitas D., ŞENDUR M. A. N., Karaca H., Ozdemir N., AKSOY S., Berk V., et al.
Asian Pacific Journal of Cancer Prevention , cilt.16, sa.4, ss.1471-1477, 2015 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

56. Trastuzumab-based retreatment after lapatinib in heavily pretreated HER2 positive metastatic breast cancer: An anatolian society of medical oncology study

Uncu D., Bayoglu I. V., Arslan U. Y., Kucukoner M., Artac M., Koca D., et al.
Asian Pacific Journal of Cancer Prevention , cilt.16, sa.9, ss.4127-4131, 2015 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

57. Assessment of prognostic value of "neutrophil to lymphocyte ratio" and "prognostic nutritional index" as a sytemic inflammatory marker in non-small cell lung cancer

Kos F. T., Hocazade C., Kos M., Uncu D., Karakas E., Dogan M., et al.
Asian Pacific Journal of Cancer Prevention , cilt.16, sa.9, ss.3997-4002, 2015 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

58. Duodenal adenocarcinoma: A rare cause of chyloperitoneum (chylous ascites)

Civelek B., AKSOY S., Kos T., Arik Z., Akinci M., Uncu D., et al.
Indian Journal of Cancer , cilt.52, sa.1, ss.109, 2015 (SCI-Expanded) identifier identifier identifier

59. The efficacy of adjuvant trastuzumab in HER-2 positive breast cancer with axillary lymph node metastases according to the treatment duration

ŞENDUR M. A. N., AKSOY S., Ozdemir N. Y., Yazici O., ZENGİN N., Altundag K.
Current Medical Research and Opinion , cilt.30, sa.12, ss.2535-2542, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

60. Lanreotide in metastatic enteropancreatic neuroendocrine tumors

Ozdemir N., Yazici O., ZENGİN N.
New England Journal of Medicine , cilt.371, sa.16, ss.1555-1557, 2014 (SCI-Expanded) identifier identifier identifier

61. The clinicopathological characteristics with long-term outcomes in malignant mesothelioma

Dogan M., UTKAN G., Hocazade C., Uncu D., Toptas S., Ozdemir N., et al.
Medical Oncology , cilt.31, sa.10, ss.1-6, 2014 (SCI-Expanded) identifier identifier identifier

62. Adjuvant chemotherapy outcomes in patients over 65 years with early stage colorectal carcinoma

Civelek B., AKSOY S., Sendur M. A. N., Yazici O., Kanmaz H., Kos F. T., et al.
Journal of B.U.ON. , cilt.19, sa.4, ss.906-912, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

63. Metastatic parenchymal renal squamous cell carcinoma with hypercalcemia

Açıkgöz Y., ŞENDUR M. A. N., AKSOY S., Özdemir N. Y., ZENGİN N.
Medical Oncology , cilt.31, sa.9, ss.1-2, 2014 (SCI-Expanded) identifier identifier identifier

64. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen

Sendur M. A. N., Ozdemir N., Özatlı T., Yazıcı O., Aksoy S., Ekinci A. Ş., et al.
Medical Oncology , cilt.31, sa.9, ss.1-8, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

65. Impact of acetylsalicylic acid on the clinicopathological characteristics and prognosis of patients with invasive breast cancer

Sendur M. A., AKSOY S., Ozdemir N. Y., ZENGİN N., Altundag K.
Breast Care , cilt.9, sa.4, ss.261-266, 2014 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

66. Longest progression-free survival with lapatinib and capecitabine combination followed by trastuzumab in HER2-positive brain metastatic breast cancer

Şendur M. A. N., Uncu D., ZENGİN N.
Medical Oncology , cilt.31, sa.4, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

67. Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer

Şendur M. A. N., AKSOY S., Yazici O., Ozdemir N. Y., ZENGİN N., Altundag K.
Medical Oncology , cilt.31, sa.2, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

68. Clinicopathologic features and prognosis of osteosarcoma in Turkish adults

Seker M. M., Seker A., AKSOY S., Ozdemir N., Uncu D., ZENGİN N.
Asian Pacific Journal of Cancer Prevention , cilt.15, sa.8, ss.3537-3540, 2014 (SCI-Expanded) Creative Commons License identifier identifier identifier

69. Everolimus: A new hope for patients with breast cancer

Sendur M. A., ZENGİN N., AKSOY S., Altundag K.
Current Medical Research and Opinion , cilt.30, sa.1, ss.75-87, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

70. Flurbiprofen-induced unilateral eyelid angioedema

ŞENDUR M. A. N., AKSOY S., Özdemir N. Y., Yaman Ş., ZENGİN N.
Cutis , cilt.94, sa.4, 2014 (SCI-Expanded) identifier identifier

71. Current approaches for prophylactic cranial irradiation in extrapulmonary small cell carcinoma

Yazici O., Ozdemir N. Y., Sendur M. A., AKSOY S., ZENGİN N.
Current Medical Research and Opinion , cilt.30, sa.7, ss.1327-1336, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

72. Efficacy and safety of first line Vincristine with doxorubicin, bleomycin and dacarbazine (ABOD) for Hodgkin's lymphoma: A single Institute experience

Ozdemir N., Dogan M., ŞENDUR M. A. N., Yazici O., Abali H., Yazilitas D., et al.
Asian Pacific Journal of Cancer Prevention , cilt.15, sa.20, ss.8715-8718, 2014 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

73. Evaluation of the effect of comorbidity on survival in pancreatic cancer by using "charlson Comorbidity Index" and "cumulative Illness Rating Scale"

Kos F. T., Yazici O., Civelek B., Seker M., ARIK Z., AKSOY S., et al.
Wiener Klinische Wochenschrift , cilt.126, sa.1-2, ss.36-41, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

74. Effect of port-care frequency on venous port catheter-related complications in cancer patients

Odabas H., Ozdemir N. Y., Ziraman I., AKSOY S., Abali H., Oksuzoglu B., et al.
International Journal of Clinical Oncology , cilt.19, sa.4, ss.761-766, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

75. Prognostic factors in operated stage IIIC, pathological N3a breast cancer patients

Turker I., Arslan U. Y., Yazici O., Uyeturk U., Oksuzoglu B., Budakoglu B., et al.
Breast Care , cilt.9, sa.6, ss.421-427, 2014 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

76. Can targeted programmed death-1 antibody be a new treatment approach in breast cancer

Sendur M. A. N., AKSOY S., Demirci S., Ozdemir N. Y., ZENGİN N., Altundag K.
Journal of B.U.ON. , cilt.19, sa.2, ss.584, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

77. Recurrence risk and prognostic parameters in stage I rectal cancers

Cihan S., Kucukoner M., Ozdemir N., Dane F., Sendur M. A. N., Yazilitas D., et al.
Asian Pacific Journal of Cancer Prevention , cilt.15, sa.13, ss.5337-5341, 2014 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

78. Longest survival of lung metastatic ameloblastoma with a rare cause of malignant hypercalcemia

Açikgöz Y., Sendur M. A. N., Özdemir N. Y., AKSOY S., Uncu D., ZENGİN N.
Journal of Cranio-Maxillofacial Surgery , cilt.42, sa.4, ss.277-278, 2014 (SCI-Expanded) identifier identifier identifier

79. Lung cancer screening: A comprehensive review of the literature with detailed data Akciğer Kanseri Taraması: Literatürün Güncel Veriler Eşliğinde Detaylı İncelenmesi

Acikgoz Y., ŞENDUR M. A. N., Ozdemir N. Y., AKSOY S., ZENGİN N.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.24, sa.4, ss.270-278, 2014 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

80. Serum 25-hydroxy vitamin D status is not related to steopenia/osteoporosis risk in colorectal cancer survivors

AKINCI M. B., Sendur M. A. N., AKSOY S., Yazici O., Ozdemir N. Y., Kos T., et al.
Asian Pacific Journal of Cancer Prevention , cilt.15, sa.8, ss.3377-3381, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

81. Treatment and outcomes of ewing sarcoma in Turkish Adults: A single centre experience

Seker M. M., Kos T., Ozdemir N., Seker A., AKSOY S., Uncu D., et al.
Asian Pacific Journal of Cancer Prevention , cilt.15, sa.1, ss.327-330, 2014 (SCI-Expanded) Creative Commons License identifier identifier identifier

82. Is programmed cell death ligand-1 expression required for optimal response to anti-PD-1 antibody in cancer

Sendur M. A. N., AKSOY S., Yildirim Ozdemir N., AKINCI M. B., ZENGİN N., Altundag K.
Journal of B.U.ON. , cilt.19, sa.2, ss.577-578, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

83. Acupuncture as a complementary treatment for cancer patients receiving chemotherapy

Tas D., Uncu D., Sendur M. A., Koca N., ZENGİN N.
Asian Pacific Journal of Cancer Prevention , cilt.15, sa.7, ss.3139-3144, 2014 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

84. Evaluation of erectile dysfunction risk factors in young male survivors of colorectal cancer

Sendur M. A. N., AKSOY S., Ozdemir N. Y., Yaman S., Yazici O., AKINCI M. B., et al.
Journal of B.U.ON. , cilt.19, sa.1, ss.115-123, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

85. Necrotizing fasciitis secondary to bevacizumab treatment for metastatic rectal adenocarcinoma

Şendur M. A., AKSOY S., Özdemir N. Y., ZENGİN N.
Indian Journal of Pharmacology , cilt.46, sa.1, ss.125-126, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

86. Analysis of resected gastric cancer in Turkish population.

Demir G., Unsal D., ZENGİN N., Er O., Dane F., Yalçin S., et al.
Hepato-gastroenterology , cilt.61, sa.129, ss.259-266, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

87. Docetaxel, cisplatin, and fluorouracil combination in neoadjuvant setting in the treatment of locally advanced gastric adenocarcinoma: Phase II NEOTAX study

Ozdemir N., Abali H., Vural M., YALÇIN Ş., Oksuzoglu B., Civelek B., et al.
Cancer Chemotherapy and Pharmacology , cilt.74, sa.6, ss.1139-1147, 2014 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

88. A comparative study of low-profile and regular type totally implantable venous access devices in patients with malignant tumors: Retrospective analysis of 4501 implantations Malign tümörlü olgularda düşük profilli ve standard tip TİVEC kullani{dotless}mi{dotless}ni{dotless}n karşi{dotless}laşti{dotless}rmali{dotless} çali{dotless}şmasi{dotless}: 4501 olgunun retrospektif analizi

Akmangit I., Dede D., Daglioglu E., Sayin B., Peker A., Uncu D., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.24, sa.2, ss.97-105, 2014 (SCI-Expanded) Creative Commons License identifier identifier

89. Predictors of outcome in patients with advanced nonseminomatous germ cell testicular tumors

Yetisyigit T., Babacan N., ÜRÜN Y., Seber E. S., Cihan S., Arpaci E., et al.
Asian Pacific Journal of Cancer Prevention , cilt.15, sa.2, ss.831-835, 2014 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

90. Bevacizumab + capecitabine as maintenance therapy after initial bevacizumab + XELOX treatment in previously untreated patients with metastatic colorectal cancer: Phase iii 'stop and go' study results - A turkish oncology group trial

YALÇIN Ş., Uslu R., Dane F., Yilmaz U., ZENGİN N., Buyukunal E., et al.
Oncology (Switzerland) , cilt.85, sa.6, ss.328-335, 2013 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

91. A rare coincidence: Facioscapulohumeral muscular dystrophy and breast cancer

Yazici O., AKSOY S., Ozdemir N., Sendur M., Dogan M., ZENGİN N.
Experimental Oncology , cilt.35, sa.4, ss.311-312, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

92. Clinicopathologic features of gastric cancer in young patients

Seker M., AKSOY S., Ozdemir N., Uncu D., ZENGİN N.
Saudi Journal of Gastroenterology , cilt.19, sa.6, ss.258-261, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

93. Capecitabine/cisplatin doublet in anthracycline and taxane pretreated and HER-2 negative metastatic breast carcinoma patients

Ozdemir N., AKSOY S., Sendur M., Akinci M., Yazici O., Budakoglu B., et al.
Journal of B.U.ON. , cilt.18, sa.4, ss.831-837, 2013 (SCI-Expanded) identifier identifier identifier

94. Comparative efficacy study of 5-year letrozole or anastrozole in postmenopausal hormone receptor-positive early breast cancer

Sendur M., AKSOY S., ZENGİN N., Altundag K.
Journal of B.U.ON. , cilt.18, sa.4, ss.838-844, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

95. Arrhythmias during and after zoledronic acid infusion patients with bone metastasis

Yazici O., Aksoy S., Ucar O., Ozdemir N., Demir M., Sendur M. A. N., et al.
Medical Oncology , cilt.30, sa.3, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

96. Duration of anti-HER2 blockage therapy may improve survival in HER2 positive metastatic breast carcinoma patients

Arslan U., Turker I., AKSOY S., Oksuzoglu B., Helvaci K., Yildirim Ozdemir N., et al.
Journal of B.U.ON. , cilt.18, sa.3, ss.585-593, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

97. Variations in tumor marker levels in metastatic breast cancer patients according to tumor subtypes

Kos T., AKSOY S., Sendur M., ARIK Z., Civelek B., Kandemir N., et al.
Journal of B.U.ON. , cilt.18, sa.3, ss.608-613, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

98. Does trastuzumab-emtansine have better cardiac safety profile in contrast to trastuzumab?

Sendur M. A. N., AKSOY S., Ozdemir Y., ZENGİN N., Altundag K.
Journal of B.U.ON. , cilt.18, sa.3, ss.801, 2013 (SCI-Expanded) identifier identifier identifier

99. Evaluation of the renal function using cystatin C level in the patients receiving cisplatin-based chemotherapy

Kos F., Sendur M., AKSOY S., Sezer S., Civelek B., Yazici O., et al.
Renal Failure , cilt.35, sa.5, ss.705-710, 2013 (SCI-Expanded) identifier identifier identifier

100. Breast cancer in octogenarian women: Clinical characteristics and outcome

Kuzan T., Koca E., Dizdar O., Arslan C., Eren T., Yalcin S., et al.
Journal of B.U.ON. , cilt.18, sa.2, ss.328-334, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

101. Tyrosine kinase inhibitors may change the metastatic pattern

Sendur M. A. N., AKSOY S., Ozdemir N., ZENGİN N.
Journal of B.U.ON. , cilt.18, sa.2, ss.544, 2013 (SCI-Expanded) identifier identifier identifier

102. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: Retrospective analysis of 667 patients anatolian society of medical oncology

Uncu D., Aksoy S., Çetin B., Yetişyiǧit T., Özdemir N., Berk V., et al.
Oncology (Switzerland) , cilt.84, sa.4, ss.240-245, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

103. Evaluation of renal function using the level of neutrophil gelatinase-associated lipocalin is not predictive of nephrotoxicity associated with cisplatin-based chemotherapy

Tugba Kos F., Sendur M. A. N., AKSOY S., Celik H. T., Sezer S., Civelek B., et al.
Asian Pacific Journal of Cancer Prevention , cilt.14, sa.2, ss.1111-1114, 2013 (SCI-Expanded) identifier identifier identifier

104. Detection of circulating tumor cells in breast cancer patients: Prognostic predictive role

Turker I., Uyeturk U., Sonmez O. U., Oksuzoglu B., Helvaci K., Arslan U. Y., et al.
Asian Pacific Journal of Cancer Prevention , cilt.14, sa.3, ss.1601-1607, 2013 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

105. Importance of serum SELDI-TOF-MS analysis in the diagnosis of early lung cancer

Şimşek C., Sónmez Ó., YURDAKUL A. S., Ózmen F., ZENGİN N., Keyf A. I., et al.
Asian Pacific Journal of Cancer Prevention , cilt.14, sa.3, ss.2037-2042, 2013 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

106. Does zoledronic acid have additive effect on suppression of plasma estrogen levels?

Şendur M. A. N., AKSOY S., Özdemir N. Y., Akinci M. B., ZENGİN N., Altundaǧ K.
Asian Pacific Journal of Cancer Prevention , cilt.14, sa.1, ss.607-608, 2013 (SCI-Expanded) Creative Commons License identifier identifier identifier

107. Is exon mutation analysis needed for adjuvant treatment of gastrointestinal stromal tumor?

Şendur M. A. N., Özdemir N. Y., Akinci M. B., Uncu D., ZENGİN N., AKSOY S.
World Journal of Gastroenterology , cilt.19, sa.1, ss.144-146, 2013 (SCI-Expanded) identifier identifier identifier

108. Administration of contrast media just before cisplatin-based chemotherapy increases cisplatin-induced nephrotoxicity

Sendur M. A. N., AKSOY S., Yaman S., Arik Z., Tugba Kos F., AKINCI M. B., et al.
Journal of B.U.ON. , cilt.18, sa.1, ss.274-280, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

109. Demographic features and factors affecting overall survival in patients with hepatocellular carcinoma: A retrospective analysis in Turkey

Uyeturk U., Kos F. T., Helvaci K., Sonmez O. U., Turker I., Aktas G., et al.
Acta Medica Mediterranea , cilt.29, sa.4, ss.617-623, 2013 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

110. Is HER2 overexpression sufficient for optimal response to Pertuzumab?

Şendur M. A. N., AKSOY S., Yaman Ş., Özdemir N. Y., ZENGİN N.
Medical Oncology , cilt.29, sa.4, ss.2565-2566, 2012 (SCI-Expanded) identifier identifier identifier

111. Demographic and clinico-pathological characteristics of breast cancer patients with history of oral alendronate use

Şendur M. A. N., AKSOY S., Yaman Ş., ArIk Z., Özdemir N. Y., ZENGİN N., et al.
Medical Oncology , cilt.29, sa.4, ss.2601-2605, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

112. Efficacy of adjuvant aromatase inhibitor in hormone receptor-positive postmenopausal breast cancer patients according to the body mass index

Şendur M., AKSOY S., ZENGİN N., Altundag K.
British Journal of Cancer , cilt.107, sa.11, ss.1815-1819, 2012 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

113. New treatment trends in small cell carcinoma of the urinary bladder

Sendur M. A. N., AKSOY S., Yazici O., Akinci M., Ozdemir N., ZENGİN N.
Journal of B.U.ON. , cilt.17, sa.4, ss.799-800, 2012 (SCI-Expanded) identifier identifier identifier

114. Multiple primary malignant neoplasms: Multi-center results from Turkey

Babacan N., Aksoy S., Cetin B., Ozdemir N., Benekli M., Uyeturk U., et al.
Journal of B.U.ON. , cilt.17, sa.4, ss.770-775, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

115. Dermatomyositis complicated with a soft tissue sarcoma

Şendur M. A. N., AKSOY S., Yaman Ş., Arik Z., Kilinç L., ZENGİN N.
Rheumatology International , cilt.32, sa.10, ss.3329-3330, 2012 (SCI-Expanded) identifier identifier identifier

116. Frequency of HCV infection in renal cell carcinoma patients

Budakoǧlu B., Aksoy S., Arslan Ç., Üyetürk Ü., Babacan N. A., Özcan M. F., et al.
Medical Oncology , cilt.29, sa.3, ss.1892-1895, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

117. Isolated testicular metastasis of gastric cancer

Civelek B., Aksoy S., Kös T., Şeker M. M., Arik Z., Şendur M. A. N., et al.
Journal of Gastrointestinal Cancer , cilt.43, sa.SUPPL. 1, 2012 (SCI-Expanded) identifier identifier

118. Retrospective analysis of seventy-one patients with neuroendocrine tumor and review of the literature

Dogan M., Yalcin B., Ozdemir N. Y., Arslan U. Y., Dogan L., UTKAN G., et al.
Medical Oncology , cilt.29, sa.3, ss.2021-2026, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

119. Can bevacizumab be a new treatment approach in metastatic melanoma?

Nahit Sendur M. A., Ozdemir N., AKSOY S., Akinci M., ZENGİN N.
Journal of B.U.ON. , cilt.17, sa.3, ss.601-602, 2012 (SCI-Expanded) identifier identifier identifier

120. Plasma VEGF levels may not accurately reflect the truth all the time

Şendur M. A. N., AKSOY S., Yaman Ş., Arik Z., Özdemir N. Y., ZENGİN N.
Medical Oncology , cilt.29, sa.2, ss.1403-1404, 2012 (SCI-Expanded) identifier identifier identifier

121. Successful treatment of chronic hiccup with baclofen in cancer patients

Şeker M. M., AKSOY S., Özdemir N. Y., Uncu D., Civelek B., Akinci M. B., et al.
Medical Oncology , cilt.29, sa.2, ss.1369-1370, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

122. Pertuzumab plus trastuzumab in metastatic breast cancer [1]

Şendur M. A. N., AKSOY S., ZENGİN N.
New England Journal of Medicine , cilt.366, sa.14, ss.1348-1350, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

123. Evaluation of relationship between serum protein profiles and lung cancer by SELDI-TOF-MS (surface enhanced laser desabsorbtion ionization time of flight mass spectrometry) method Akciǧer kanseri ile serum protein profılleri arasındaki i̇lişkinin SELDI-TOF-MS (Surface enhanced laser desabsorbation ionization time of flight mass spectrometry) yöntemi ile deǧerlendirilmesi

YURDAKUL A. S., Sönmez Ö., Şimşek C., ZENGİN N., Keyf A. I., ÖZTÜRK C., et al.
Turkiye Klinikleri Journal of Medical Sciences , cilt.32, sa.4, ss.1084-1089, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

124. Lymphoproliferative disorders in multiple primary cancers

Demirci U., ÖZDEMİR N., Benekli M., Babacan N. A., Cetin B., Baykara M., et al.
Asian Pacific Journal of Cancer Prevention , cilt.13, sa.1, ss.383-386, 2012 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

125. Hyperkalemia in a patient with advanced hepatocellular carcinoma probably due to sorafenib: Case report I{cyrillic, ukrainian}lerlemiş hepatoselüler karsinomlu hastada muhtemelen Sorafenibe baǧ olan hiperkalemi

Üyetürk Ü., Budakoǧlu B., Helvaci K., Uysal Sönmez Ö., Türker I., Yalçintaş Arslan Ü., et al.
Turkiye Klinikleri Journal of Medical Sciences , cilt.32, sa.2, ss.585-587, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

126. Small cell carcinoma of the urinary bladder with hypercalcemia

Şendur M. A. N., AKSOY S., Arik Z., Yaman Ş., Özdemir N. Y., Uncu D., et al.
Medical Oncology , cilt.29, sa.2, ss.827-828, 2012 (SCI-Expanded) identifier identifier identifier

127. Prognostic factors and treatment outcomes in 93 patients with uterine sarcoma from 4 centers in Turkey

Durnali A., Tokluoǧlu S., Özdemir N., İNANÇ M., Alkiş N., ZENGİN N., et al.
Asian Pacific Journal of Cancer Prevention , cilt.13, sa.5, ss.1935-1941, 2012 (SCI-Expanded) Creative Commons License identifier identifier identifier

128. Abo and rh blood groups and risk of colorectal adenocarcinoma

Ürün Y., Özdemir N. Y., Utkan G., Akbulut H., Savaş B., Öksüzoǧlu B., et al.
Asian Pacific Journal of Cancer Prevention , cilt.13, sa.12, ss.6097-6100, 2012 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

129. Taxanes in the adjuvant treatment of node-negative breast cancer patients

Ozdemir N., AKSOY S., ZENGİN N., Altundag K.
Journal of B.U.ON. , cilt.17, sa.1, ss.27-32, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

130. Imatinib-induced anasarca without heart failure: Capillary leakage?

Nahit Sendur M., Aksoy S., Civelek B., ZENGİN N., AKSOY S.
Journal of B.U.ON. , cilt.17, sa.1, ss.188-189, 2012 (SCI-Expanded) identifier identifier identifier

131. Is there an association between blood group and survival in pancreatic cancer?

Kos F. T., Civelek B., ŞEKER M., ARIK Z., AKSOY S., Uncu D., et al.
Asian Pacific Journal of Cancer Prevention , cilt.13, sa.12, ss.6151-6153, 2012 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

132. Efficacy of angiotensin-receptor blockers on demographic and clinico-pathological characteristics of breast cancer

Şendur M. A., AKSOY S., Yaman S., Ozdemir N. Y., ZENGİN N., Altundag K.
Breast , cilt.21, sa.3, ss.419-420, 2012 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

133. Safety and efficacy of FOLFIRI-bevacizumab for metastatic colorectal carcinoma as second line treatment

Odabas H., Ozdemir N., Isik M., Abali H., Oksuzoglu B., Kos T., et al.
Journal of B.U.ON. , cilt.16, sa.3, ss.460-463, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

134. Adjuvant therapy for gallbladder and bile duct cancers: Retrospective comparative study

Tugba Kos F., AKSOY S., Odabas H., Ozdemir N., Oksuzoglu B., Uncu D., et al.
Journal of B.U.ON. , cilt.16, sa.3, ss.464-468, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

135. Gemcitabine and cisplatin in patients with carcinoma of unknown primary site

Isik M., Seker M. M., Odabas H., Kos F. T., Uncu D., ZENGİN N.
Medical Oncology , cilt.28, sa.2, ss.591-596, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

136. Comparison of cisplatin-5-fluorouracil-folinic acid versus modified docetaxel-cisplatin-5-fluorouracil regimens in the first-line treatment of metastatic gastric cancer

Kos F. T., Uncu D., Özdemir N., Budakoglu B., Odabaş H., Abali H., et al.
Chemotherapy , cilt.57, sa.3, ss.230-235, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

137. Long term survival in a metastatic alveolar soft part sarcoma at the time of diagnosis: A case with 17 years of follow-up

Kos F. T., Uncu D., Oksuzoglu B., AKSOY S., Ozdemir N., Odabas H., et al.
Journal of B.U.ON. , cilt.16, sa.2, ss.376-377, 2011 (SCI-Expanded) identifier identifier identifier

138. Gastric adenocarcinoma under the age of 40; more metastatic, less differentiated

Isik M., Caner S., Metin Seker M., Civelek B., Odabas H., Ozdemir N., et al.
Journal of B.U.ON. , cilt.16, sa.2, ss.253-256, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

139. First-line therapy for metastatic colorectal carcinoma: Modified FOLFOX4 or FOLFIRI-bevacizumab

Odabas H., Ozdemir N., Abali H., Oksuzoglu B., Isik M., Uncu D., et al.
Journal of B.U.ON. , cilt.16, sa.2, ss.247-252, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

140. Successful management of bevacizumab-associated surgical bleeding with an ankaferd blood stopper

Ozdemir N., AKSOY S., Eren T., Uncu D., Bülent Akinci M., Alaguney M. E., et al.
Asian Pacific Journal of Cancer Prevention , cilt.12, sa.4, ss.1103-1104, 2011 (SCI-Expanded) identifier identifier

141. Bevacizumab: A new potential therapeutic option in sinusoidal obstruction syndrome

Şendur M. A. N., AKSOY S., Arik Z., Yaman Ş., Özdemir N. Y., Uncu D., et al.
Asian Pacific Journal of Cancer Prevention , cilt.12, sa.8, ss.2147-2148, 2011 (SCI-Expanded) identifier identifier

142. Rapid pleurodesis in malignant pleural effusion: A clinical study and literature review Malign plevra efüzyonunda hızlı plörodez: Klinik çalışma ve literatür derlemesi

Yazkan R., Yildirim E., Dural K., ZENGİN N., Sakinci Ü.
Turkish Journal of Thoracic and Cardiovascular Surgery , cilt.19, sa.3, ss.410-416, 2011 (SCI-Expanded) identifier identifier

143. Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma.

Cihan Ş., Uncu D., Babacan N. A., Özdemir N., Odabaş H., AKSOY S., et al.
Asian Pacific journal of cancer prevention : APJCP , cilt.12, sa.4, ss.967-970, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

144. Breast cancer subtypes and outcomes of central nervous system metastases

Arslan U. Y., Oksuzoglu B., AKSOY S., Harputluoglu H., Turker I., Ozisik Y., et al.
Breast , cilt.20, sa.6, ss.562-567, 2011 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

145. The efficacy and safety of reduced-dose docetaxel, cisplatin, and 5-fluorouracil in the first-line treatment of advanced stage gastric adenocarcinoma

Özdemir N. Y., AbalI H., Öksüzoǧlu B., Budakoglu B., Uncu D., Güler T., et al.
Medical Oncology , cilt.27, sa.3, ss.680-684, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

146. Fifty-one Kaposi sarcoma patients

Dogan M., Dogan L., Ozdemir F., Yildirim Ozdemir N., Senol Coskun H., Yalcintas Arslan U., et al.
Clinical and Translational Oncology , cilt.12, sa.9, ss.629-633, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

147. Adjuvant bi-weekly combination of cisplatin, infusional 5-fluorouracil and folinic acid followed by concomitant chemoradiotherapy with infusional fluorouracil for high risk operated gastric and gastroesophageal junction adenocarcinoma

Uncu D., Ozdemir N. Y., AKSOY S., Abali H., Oksuzoglu B. C., Budakoglu B., et al.
Asian Pacific Journal of Cancer Prevention , cilt.11, sa.6, ss.1493-1497, 2010 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

148. It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting

Özdemir N. Y., AbalI H., Öksüzoǧlu B., Budakoǧlu B., Akmangit I., ZENGİN N.
Supportive Care in Cancer , cilt.17, sa.4, ss.399-403, 2009 (SCI-Expanded) identifier identifier identifier

149. Capecitabine and cisplatin combination is an active and well-tolerated doublet in the treatment of metastatic breast carcinoma patients pretreated with anthracycline and taxanes

Öksüzoglu B., Abali H., HAYRAN K. M., Yildirim N., Budakoglu B., ZENGİN N.
Chemotherapy , cilt.54, sa.5, ss.352-356, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

150. Prognostic factors and clinicopathological characteristics of carcinoma of ampulla vateri

Pamukcuoglu M., Oksuzoglu B., Abali H., Akoglu M., Atalay F., Budakoglu B., et al.
International Surgery , cilt.93, sa.4, ss.214-219, 2008 (SCI-Expanded) identifier identifier identifier

151. Comparison of ICE (Ifosfamide-Carboplatin-Etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma

Abali H., ÜRÜN Y., Öksüzoǧlu B., Budakoǧlu B., Yüldürüm N., Güler T., et al.
Cancer Investigation , cilt.26, sa.4, ss.401-406, 2008 (SCI-Expanded) identifier identifier identifier

152. Intraabdominal desmoplastic small round cell tumor mimicking renal cell cancer: A case report and review of the literature Böbrek hücreli kanseri taklit eden abdominal kaynakli desmoplastik kücük yuvarlak hücreli tümör: Bir olgu sunumu ve yayinlarin gözden geçirilmesi

Tuncel A., Aslan Y., Yildirim Ü., ZENGİN N., Atan A.
Turk Uroloji Dergisi , cilt.34, sa.1, ss.128-132, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma identifier

153. Whole body 18F-FDG PET/CT imaging in the detection of primary tumours in patients with a metastatic carcinoma of unknown origin

KAYA A., UĞUR Ş., ÜNLÜ M., AKDEMİR Ü. Ö., Ozdemir N. Y., ZENGİN N., et al.
Asian Pacific Journal of Cancer Prevention , cilt.9, sa.4, ss.683-686, 2008 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

154. The effect of regimes of harvesting autologous peripheric stem cell on the number of CD34(+) cell: Experience at a single center Otolog periferik kök hücre toplama rejimlerinin CD34(+) hücre sayisi üzerine etkisi: Tek merkez deneyimi

Şahin Balçik Ö., Daǧdaş S., Keser Güler S., Özet G., Oymak A., Çelik Z., et al.
Turkiye Klinikleri Journal of Medical Sciences , cilt.28, sa.5, ss.640-647, 2008 (SCI-Expanded) identifier

155. Cerebrovascular accident during cisplatin-based combination chemotherapy of testicular germ cell tumor: An unusual case report

Azak A., Öksüzoǧlu B., Deren T., Öneç B. M., ZENGİN N.
Anti-Cancer Drugs , cilt.19, sa.1, ss.97-98, 2008 (SCI-Expanded) identifier identifier identifier

156. Good tolerance of high dose cytosine arabinoside and methotrexate after severe myelosuppression secondary to intrathecal administration of the same agents

Yildirim N., Abali H., Güler T., Öksüzoǧlu B., Pamukçu M., ZENGİN N.
Turkish Journal of Hematology , cilt.24, sa.3, ss.140-141, 2007 (SCI-Expanded) identifier

157. Multiple myeloma in a patient with neurofibromatosis [1]

ZENGİN N., Gönül M., Gül Ü., Öksüzoǧlu B., Kiliç A., Çakmak S. K., et al.
American Journal of Hematology , cilt.82, sa.8, ss.772, 2007 (SCI-Expanded) identifier identifier identifier

158. Blood flow indices by doppler ultrasonography vary with neoadjuvant chemotherapy but are not related to plasma VEGF levels in locally advanced breast cancer

Öksüzoǧlu B., Vural M., Abali H., Yilmaz M., Yildirim N., ZENGİN N.
Oncology , cilt.71, sa.3-4, ss.185-189, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

159. Tamoxifen induced-thrombocytopenia: It does occur

Nasıroğlu N., Pamukçuoğlu M., Abalı H., Öksüzoğlu B., ÜNER A., ZENGİN N.
Medical Oncology , cilt.24, sa.4, ss.453-454, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

160. An extraordinary case in whom gastrointestinal stromal tumor and low-grade malignant lymphoma are seen together in the stomach

Pamukçuoğlu M., Budakoğlu B., Han Ö., Tad M., Öksüzoğlu B., Abalı H., et al.
Medical Oncology , cilt.24, sa.3, ss.351-353, 2007 (SCI-Expanded) identifier identifier identifier

161. Cavernous sinus syndrome caused by metastatic colon carcinoma

Öneç B., Öksüzoǧlu B., Hatipoǧlu H. G., Öneç K., Azak A., ZENGİN N.
Clinical Colorectal Cancer , cilt.6, sa.8, ss.593-596, 2007 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

162. Sinonasal NK/T-cell lymphoma mimicking Wegener's granulomatosis: A case report Wegener granülomatozisi taklit eden sinonazal böige tutulumlu NK/T-hücreli lenfoma: Olgu sunumu

Pamukçuoǧlu M., Nasiroǧlu N., Yildirim N., Özçelik Ö., Öksüzoǧlu B., Abali H., et al.
Tuberkuloz ve Toraks , cilt.54, sa.3, ss.277-280, 2006 (SCI-Expanded) identifier identifier

163. Prognostic factors of non-Hodgkin lymphoma Non-Hodgkin lenfomada prognostik parametreler

Uncu D., Abali H., Özdemir N., Budakoǧlu B., Güler T., Öksüzoǧlu B. Ç., et al.
UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.16, sa.1, ss.27-31, 2006 (SCI-Expanded) identifier

164. Performance status scales may not correctly predict status of cancer patients with paraplegia

Budakoglu B., Abali H., Çakmaköksüzoglu B., AKSOY S., ZENGİN N.
Cancer Investigation , cilt.24, sa.2, ss.221-222, 2006 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

165. Disclosure of cancer diagnosis to patients and their relatives in Turkey: Views of accompanying persons and influential factors in reaching those views

Öksüzoǧlu B., Abali H., Bakar M., Yildirim N., ZENGİN N.
Tumori , cilt.92, sa.1, ss.62-66, 2006 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier

166. Cisplatin plus oral etoposide (EoP) combination is more effective than paclitaxel in patients with advanced breast cancer pretreated with anthracyclines: A randomised phase III trial of Turkish Oncology Group

Icli F., Akbulut H., Uner A., Yalcin B., Baltali E., Altinbas M., et al.
British Journal of Cancer , cilt.92, sa.4, ss.639-644, 2005 (SCI-Expanded) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

167. Rapid pleurodesis in symptomatic malignant pleural effusion

Yildirim E., Dural K., Yazkan R., ZENGİN N., Yildirim D., Gunal N., et al.
European Journal of Cardio-thoracic Surgery , cilt.27, sa.1, ss.19-22, 2005 (SCI-Expanded) Creative Commons License identifier identifier identifier

168. Case report: Cavernous sinus metastasis of the parotid carcinoma: A very unusual case

Yıldırım N., Üksüzoǧlu B., Vural M., Han Ö., ZENGİN N.
Journal of Neuro-Oncology , cilt.73, sa.2, ss.181-183, 2005 (SCI-Expanded) identifier identifier identifier

169. Primary duodenal diffuse large cell non-hodgkin lymphoma with involvement of ampulla of Vater: Report of 3 cases

Yildirim N., Öksüzoǧlu B., Budakoǧlu B., Vural M., Abal H., Uncu D., et al.
Hematology , cilt.10, sa.5, ss.371-374, 2005 (SCI-Expanded) identifier identifier identifier

170. Good tolerance of weekly irinotecan in a patient with metastatic colorectal cancer on chronic hemodialysis

Budakoglu B., Abali H., Uncu D., Yildirim N., Öksüzoglu B., ZENGİN N.
Journal of Chemotherapy , cilt.17, sa.4, ss.452-453, 2005 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

171. Prospective study of combined modality treatment or radiotherapy alone in the management of early-stage adult Hodgkin's disease

YILDIZ F., ZENGİN N., Engin H., Güllü I., BARIŞTA İ., Çaglar M., et al.
International Journal of Radiation Oncology Biology Physics , cilt.60, sa.3, ss.839-846, 2004 (SCI-Expanded) identifier identifier identifier

172. Analysis of menstrual, reproductive, and life-style factors for breast cancer risk in turkish women: A case-control study

Oran B., ÇELİK İ., ERMAN M., Baltali E., ZENGİN N., DEMİRKAZIK F., et al.
Medical Oncology , cilt.21, sa.1, ss.31-39, 2004 (SCI-Expanded) Sürdürülebilir Kalkınma identifier identifier identifier

173. Use of hydroxyurea and α-interferon in chronic myeloid leukemia during pregnancy: A case report

Baykal C., ZENGİN N., COŞKUN F. M., Güler N., Ayhan A.
European Journal of Gynaecological Oncology , cilt.21, sa.1, ss.89-90, 2000 (SCI-Expanded) identifier identifier

174. Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy

Barişta I., Tekuzman G., Yalçin Ş., Güllü I., Güler N., Özişik Y., et al.
Journal of Surgical Oncology , cilt.73, sa.1, ss.12-16, 2000 (SCI-Expanded) identifier identifier identifier

175. Paclitaxel in the salvage treatment of metastatic breast carcinoma

Guler N., Baltali E., Altundag K., ZENGİN N., Tekuzman G., Ozisik Y., et al.
Journal of B.U.ON. , cilt.4, sa.3, ss.275-281, 1999 (SCI-Expanded) identifier

176. The significance of the bone marrow biopsy pattern in chronic lymphocytic leukemia: A prognostic dilemma

ZENGİN N., Kars A., Sungur A., Zengin N. I., HAYRAN K. M., Tekuzman G., et al.
American Journal of Hematology , cilt.62, sa.4, ss.208-211, 1999 (SCI-Expanded) identifier identifier identifier

177. Acute lymphoblastic leukaemia presenting with arthritis in an adult patient

Usalan C., Özarslan E., ZENGİN N., Büyükaýk Y., Güllü Ý. H.
Postgraduate Medical Journal , cilt.75, sa.885, ss.425-427, 1999 (SCI-Expanded) Creative Commons License identifier identifier identifier

178. Primary neuroendocrine tumor of the breast

YALÇIN Ş., ZENGİN N., Tekuzman G., Küçükali T.
Medical Oncology , cilt.14, sa.2, ss.121-123, 1997 (SCI-Expanded) identifier identifier identifier

179. Maintenance therapy with alpha-interferon following first-line VAD in multiple myeloma

Kars A., Çelik I., Kansu E., Tekuzman G., Özişik Y., Güler N., et al.
European Journal of Haematology , cilt.59, sa.2, ss.100-104, 1997 (SCI-Expanded) identifier identifier

180. High-dose ifosfamide by infusion with Mesna in advanced refractory sarcomas

Güllü I., YALÇIN Ş., Tekuzman G., BARIŞTA İ., Alkiş N., ÇELİK İ., et al.
Cancer Investigation , cilt.14, sa.3, ss.239-242, 1996 (SCI-Expanded) identifier identifier identifier
Diğer Dergilerde Yayınlanan Makaleler 13

1. Posterior Reversible Encephalopathy Syndrome Secondary to Regorafenib in Metastastic Colon Cancer

Eruyar E., Zengin N.
Turk Onkoloji Dergisi , cilt.40, sa.2, ss.164-166, 2025 (ESCI) identifier

2. Retrospective Analysis of Multiple Sclerosis Patient Records in a Turkish reference Center

KAHVECİ R., ERUYAR E., ÖZER KÜÇÜK E., YÜKSEK Y. N., TÜTÜNCÜ T., AKSOY H., et al.
Journal of Clinical and Experimental Investigations , cilt.8, sa.3, ss.96-100, 2017 (Hakemli Dergi)

3. Squamous cell cancer of the lung with synchronous renal cell carcinoma

Ateş İ., Yazıcı O., Ateş H., Yazılıtaş D., Özcan A. N., Ağaçkıran Y., et al.
Turk Toraks Dergisi , cilt.17, sa.3, ss.125-127, 2016 (ESCI) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

4. Clinical outcomes and prognostic factors of adult's Ewing sarcoma family of tumors: Single center experience

Uyeturk U., Helvaci K., Demirci A., Sonmez O. U., Turker I., Afsar C. U., et al.
Wspolczesna Onkologia , cilt.20, sa.2, ss.141-146, 2016 (ESCI) Creative Commons License identifier identifier identifier

5. Evaluation of the effects of red blood cell distribution width on survival in lung cancer patients

Kos M., Hocazade C., Kos F. T., Uncu D., Karakas E., Dogan M., et al.
Wspolczesna Onkologia , cilt.20, sa.2, ss.153-157, 2016 (ESCI) Creative Commons License Sürdürülebilir Kalkınma identifier identifier identifier

6. Helicobacter pylori seropostivity of colon cancer Kolon Kanserinde Helikobakter Pylori Seropozitifliği

Tuğba Köş F., Sezer S., Yazıcı O., Civelek B., Yıldız A., AKSOY S., et al.
Journal of Clinical and Analytical Medicine , cilt.6, sa.1, ss.79-82, 2015 (ESCI) Creative Commons License Sürdürülebilir Kalkınma identifier identifier

7. Methodology of National Turkey Nutrition and Health survey (TNHS)

BESLER H. T., PEKCAN A. G., ZENGİN N., BAKIR F.
Medical Journal of Islamic World Academy of Sciences , cilt.22, sa.1, ss.7-29, 2014 (Hakemli Dergi)

8. Clinical features and prognostic factors of hepatocellular carcinoma patients; single center experience

ALANLI R., KÖŞ F. T., UNCU D., YAZICI O., ÖZDEMİR N., AKSOY S., et al.
TURK ONKOLOGI DERGISI-TURKISH JOURNAL OF ONCOLOGY , cilt.28, sa.4, ss.143-149, 2013 (ESCI) identifier identifier

9. Primary squamous cell carcinoma of the breast

Uncu D., Öksüzoǧlu B., Budakoǧlu B., Günce S., Özdemir N., Güler T., et al.
Turkish Journal of Cancer , cilt.39, sa.1, ss.26-27, 2009 (Scopus) Sürdürülebilir Kalkınma identifier

10. The clinical and pathological features of patients with gastric cancer in Turkey: A Turkish Oncology Group Study

Yalçin B., ZENGİN N., AYDIN F., Ilhan M., Işikdoǧan A., Demir G., et al.
Turkish Journal of Cancer , cilt.36, sa.3, ss.108-115, 2006 (Scopus) Sürdürülebilir Kalkınma identifier

11. Primary extranodal lymphoma: The comparison of clinical characteristics with nodal lymphoma Primer ekstranodal lenfomalar: Klinik özelliklerinin nodal lenfomalarla karşilaştirilmasi

Uncu D., Özdemir N., Karakan Ş., Öksüzoǧlu B. Ç., ZENGİN N.
THOD - Turk Hematoloji-Onkoloji Dergisi , cilt.15, sa.2, ss.63-67, 2005 (Scopus) identifier

12. Retrospective Evaluation of Adults with Soft Tissue Ewing Sarcoma and Primitive Neuroectodermal Tumors Yumuşak Doku Ewing Sarkomu ve Primitif Nöroektodermal Tümörlü Erişkin Olgularin Retrospektif Deǧerlendirilmesi

Karakan Š., Öksüzoǧlu B., Uncu D., Yildirim N., Budakoǧlu B., Küçükazman M., et al.
THOD - Turk Hematoloji-Onkoloji Dergisi , cilt.14, sa.1, ss.14-19, 2004 (Scopus) identifier

13. Docetaxel (Taxotere) in the salvage treatment of anthracycline resistant metastatic breast cancer

Guler N., Baltali E., Altundag K., ZENGİN N., Ozisik Y., Tekuzman G., et al.
Turkish Journal of Cancer , cilt.29, sa.3, ss.119-129, 1999 (Scopus) Sürdürülebilir Kalkınma identifier
Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 1

1. MİDE KANSERLİ BİR HASTADA DOSETAKSEL İLİŞKİLİ AKUT MİYOZİT

Eruyar E., Zengin N.
. 10 th International Hippocrates Congress on Medical and Health Sciences, Ankara, Türkiye, 16 - 17 Aralık 2022, ss.163-166, (Tam Metin Bildiri) Creative Commons License Sürdürülebilir Kalkınma
Metrikler

Yayın

194

Yayın (WoS)

163

Yayın (Scopus)

191

Atıf (WoS)

1114

H-İndeks (WoS)

17

Atıf (Scopus)

1327

H-İndeks (Scopus)

18

Tez Danışmanlığı

2

Açık Erişim

41
BM Sürdürülebilir Kalkınma Amaçları